FidoCure®

Our Founder and CEO Christina Lopes featured in The Cancer Letter stressing the application of data and AI in the research of comparative oncology. Read the full article below to get insight into our mission and how AI is leading the fight against cancer on both ends of the leash.

Today on World Veterinary Day, we are so grateful for the 1100 veterinarians in over 1050+ clinics around the world who work tirelessly with FidoCure® to diagnose, treat, and manage cancer in dogs. Through our FidoCure platform, they provide cutting-edge treatments and personalized care for each canine patient in need. Together, we are at the forefront of the fight against canine cancer, offering hope and healing to dogs and their families. Thank you to all the veterinarians who make this possible including those featured below from FidoCure® pet parents across the globe. #worldveterinaryday #veterinarymedicine #fidocure

Celebrate National DNA Day with FidoCure! 🧬 On this day in 1953, James Watson, Francis Crick, and colleagues like Rosalind Franklin unveiled the landmark discovery of DNA's double helix structure. Their pioneering work, published in the journal Nature, unlocked the secrets of life's genetic code. Fast forward to today, and FidoCure's team and scientists at Stanford University have followed in those footsteps by collecting a vast amount of 1.7 billion data points on canine cancer and publishing groundbreaking studies in Nature NPJ Precision Oncology and Nature Scientific Reports. Our research utilized cutting-edge genetic sequencing to identify existing human cancer drugs for canine cancer - and demonstrated an overall 2-3x longer life expectancy than traditional treatments! Just as the double helix discovery paved the way for modern genetics, FidoCure's findings bring new treatments to improve the lives of our beloved pets. We're unraveling pet health, one double helix at a time! Join us in celebrating the past and future of DNA science by viewing the research here. Press (fidocure.com) Like, share, and follow FidoCure for more updates from the frontier of genetics and veterinary medicine. #NationalDNADay #FidoCure #PetHealth #GeneticSequencing #DNADoubleHelix

FidoCure® Celebrates Significant Milestone: 5,000 Dog Enrolled We are proud to announce that FidoCure, in collaboration with our veterinary partners, global health researchers, A.I leaders and our pet parents have reached a significant milestone by enrolling over 5,000 dogs in our canine cancer treatment platform. The 5,000 dogs enrolled have contributed to groundbreaking research that we’ve had the opportunity to publish in Nature NPJ Precision Oncology, Nature Scientific Reports, Elsevier Veterinary Clinics of Small Animal Practice and Wiley Veterinary and Comparative Oncology, showcasing the groundbreaking insights we have gained through this remarkable journey with our partners. (View research here: https://lnkd.in/gdWF6yBy) We extend our heartfelt gratitude to the veterinary community, our research partners, pet parents, and the entire team at FidoCure for their trust and dedication. Together, we are making a positive impact on the lives of dogs and their families. As we move forward, FidoCure remains committed to fighting cancer on both ends of the leash. We’re expanding our reach, refining our platform, and advancing canine cancer research to benefit even more dogs and humans in the future. Thank you for being a vital part of the FidoCure community! #FidoCure5000 #CanineCancerResearch #VeterinaryMedicine #FidoCure

FidoCure® is honored to announce that Dr. Fabian Kausche, a renowned leader in animal and human healthcare, has joined FidoCure's advisory board. With his extensive experience and expertise, Dr. Kausche will play a crucial role in guiding our efforts to bring cutting-edge precision medicine to canine cancer treatment and global research. Dr. Kausche's impressive career spans across top global animal health companies, including Novartis Animal Health, Merial, and Boehringer Ingelheim Animal Health, where he held positions as Global Head of Research & Development. His expertise also extends to the human health space, having led R&D for Novartis Consumer Health. With many years of successful experience in executive committees managing multi-billion dollar businesses, he most notably held the position of Chairman of PetMedix from Series A through their successful acquisition by Zoetis. As an experienced board member and scientific advisor at various established companies, Dr. Kausche brings a wealth of knowledge and leadership skills to FidoCure. His appointment aligns with our commitment to leveraging the latest machine learning advancements in human oncology to revolutionize cancer treatment for our canine companions. We are confident that Dr. Kausche's guidance will be invaluable as we continue our mission to fight cancer on both ends of the leash. Join us in welcoming Dr. Fabian Kausche to the FidoCure team! 🐾🎉 https://lnkd.in/gJVH-dxv #FidoCure #CanineCancer #PrecisionMedicine #OneHealthCompany #AdvisoryBoard #AnimalHealth #HumanHealth

We are so proud of our 5-year relationship with the American Association for Cancer Research and the opportunity to present our research yet again at this year's conference. Dr. Lucas Rodrigues shared findings on the prognosis and treatment prediction of the PARP inhibitor olaparib, analyzed by 1278 dogs enrolled in the FidoCure platform. This monumental collaboration between FidoCure® by One Health and Stanford University led by James Zou has the potential to advance precision medicine in both veterinary and human oncology. We are honored to be recognized at such a prestigious event amongst our colleagues in the global cancer research community. #AACR #VeterinaryOncology #CancerResearch #FidoCure

Dr. Lucas Rodrigues is back from attending the #WorldVeterinaryCancerCongress in Tokyo, a quadrennial event advancing veterinary oncology education globally. Dr. Rodrigues presented to hundreds of fellow researchers our collaboration with Stanford University on soft tissue sarcoma, utilizing machine learning to analyze mutations and treatment outcomes from real-world clinico-genomic data of 335 dogs enrolled in the FidoCure® Precision Medicine platform. The conference featured groundbreaking science and research with keynote presentations by renowned speakers including one of our FidoCure® advisors Dr. Nicola Mason. Tokyo's blend of traditional and modern culture, along with its amazing culinary scene, enhanced the overall experience. The combination of exceptional conference programming and the vibrant city made the World Veterinary Cancer Conference truly enriching and memorable for our team. #WVCC #VeterinaryOncology #Tokyo #SoftTissueSarcoma #MachineLearning #FidoCure

We are thrilled to share that Lucas Rodrigues will be presenting our groundbreaking collaboration with Stanford University's renowned James Zou and his team of researchers at the #VeterinaryCancerCongress today in Tokyo! 🌍🐾 This incredible partnership with Stanford's faculty and leading scholars will highlight the potential for machine learning in veterinary oncology treatments. #WVCC2024 is the leading Veterinary Oncology Conference in the world. FidoCure, in collaboration with Stanfords A.I lab will be showcasing groundbreaking results for canine soft tissue sarcoma from the analysis of cancer mutations and treatment outcomes using real-world clinical-genomic data gathered from 335 dogs enrolled with FidoCure. We are proud to be at the forefront of this global initiative dedicated to advancing veterinary oncology education. Stay tuned in our newsletter for a recap from the conference! https://lnkd.in/dryWGMDu #FidoCure #WVCC2024 #VeterinaryOncology #PrecisionMedicine #CancerResearch  #AnimalHealth #VeterinaryInnovation #FidoCure

FidoCure’s Founder and CEO Christina Lopes sat down with Verily's President and Chief Medical Officer, former Principal Deputy Commissioner of the FDA and globally recognized leader in real-world evidence, Amy Abernethy. Both leaders arrived at the #LakeNonaImpactForum2024 to discuss the groundbreaking work being done in comparative oncology. It’s been almost 8 years since we first started this conversation with Amy Abernethy, since then she has been an integral part of our journey. Her guidance, mentorship and support have been invaluable as we continue to build out our vision at FidoCure. Together, we are making a difference in the fight against cancer on both sides of the leash. 🎗 Learn more about FidoCure by watching the full interview from the Lake Nona Impact Forum below and check out our blog post to learn more about this impactful conversation!  #FidoCure #LakeNonaImpactForum2024 #FutureOfHealthcare #AIinHealthcare #BiotechInnovation #Oncology #LNIF24 Blog: https://lnkd.in/g_yf4TBn

Today, on #InternationalWomensDay, and throughout #WomensHistoryMonth, we want to extend our deepest admiration and gratitude to the incredible women who are at the forefront of innovation and care in the biotech, cancer care, veterinary industries, and beyond. A special shoutout to our visionary founder, Christina Lopes, whose leadership and dedication continue to inspire us daily. Christina's relentless pursuit of excellence in cancer treatment for both ends of the leash has not only propelled FidoCure to new heights but also spotlights the significant role of women in STEM and entrepreneurship fields. We can’t forget to celebrate the talented women on our advisory board and team, whose expertise, compassion, and resilience are the driving force in moving our mission forward. Your contributions are invaluable, and your impact is immeasurable. And to all the women making strides in biotech and cancer care, your work is changing the world, one discovery, one treatment, and one life (pet or human) at a time. Here's to breaking the glass ceiling, challenging the status quo, and creating a brighter future for tomorrow’s women! #IWD2024 #InternationalWomensDay #WomenInSTEM #WomenInBiotech #FidoCure